Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,689 across all filing types
Latest filing 2022-08-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
关于2022年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading and stock transactions related to a 2022 restricted stock incentive plan. It details the investigation of insiders and incentive recipients' stock trading activities, compliance with regulations, and concludes no misuse of insider information. The document is a regulatory announcement about insider trading compliance and stock transactions, not a financial report, earnings release, or management report. It fits best under Regulatory Filings (RNS) as it is a compliance disclosure related to insider trading and stock incentive plans.
2022-08-23 Chinese
监事会关于2022年限制性股票激励计划授予激励对象人员名单的公示情况说明及核查意见
Regulatory Filings Classification · 95% confidence The document is a statement from the Supervisory Board regarding the public disclosure and verification of the list of recipients for the 2022 restricted stock incentive plan. It discusses compliance with regulatory guidelines and internal company rules, confirming the legitimacy and eligibility of the incentive recipients. The document does not contain financial statements or performance data, nor is it an announcement of voting results or a management change. It is a regulatory compliance disclosure related to stock incentive plans, which does not fit into categories like Annual Report, Earnings Release, or Capital Update. Given its nature as a formal regulatory disclosure about internal compliance and verification, it best fits under Regulatory Filings (RNS). The document length is short and it is not a report publication announcement. Confidence is high due to clear regulatory references and the nature of the content.
2022-08-23 Chinese
2022年限制性股票激励计划（草案）摘要
Remuneration Information Classification · 95% confidence The document is a detailed draft summary of a 2022 restricted stock incentive plan for a company, including legal references, plan purpose, management, scope, stock source, quantity, allocation, effective period, grant price, conditions for grant and lifting restrictions, performance targets, accounting treatment, and handling of changes. It is a comprehensive plan document related to equity incentives for management and employees, not a financial report, earnings release, or regulatory announcement. It is not a proxy statement or voting result announcement, but a detailed plan document. This fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation plans for executives and directors, including stock incentive plans.
2022-08-11 Chinese
北京国枫律师事务所关于迪瑞医疗科技股份有限公司2022年限制性股票激励计划的法律意见书
Remuneration Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a 2022 restricted stock incentive plan for a company named 迪瑞医疗科技股份有限公司. It extensively discusses the legal compliance, conditions, procedures, and details of the stock incentive plan, including the number of shares, eligibility, vesting conditions, and regulatory adherence. The document is not a financial report, earnings release, or a simple announcement but a detailed legal opinion on a stock incentive plan, which is a form of remuneration information related to executive and employee compensation. Therefore, the document fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation plans for executives and directors, including stock incentive plans.
2022-08-11 Chinese
2022年限制性股票激励计划实施考核管理办法
Remuneration Information Classification · 95% confidence The document is titled '2022 年限制性股票激励计划实施考核管理办法' which translates to '2022 Restricted Stock Incentive Plan Implementation Assessment Management Measures'. It details the company's stock incentive plan, including performance assessment criteria, stock release schedules, and management procedures. It is a policy or management document related to stock incentives and employee compensation plans rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or earnings data, nor is it an announcement of a report. It is not related to board changes, voting results, or legal proceedings. The content fits best under Remuneration Information as it details compensation incentives and performance evaluation tied to restricted stock awards for executives and employees.
2022-08-11 Chinese
关于调整日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding adjustments to its expected daily related-party transactions for the year 2022. It includes details about the related parties, transaction amounts, pricing principles, and independent directors' opinions. The document is a formal disclosure about related-party transactions, which is a regulatory announcement typically required by stock exchanges to inform shareholders and the market about such transactions. It does not contain financial statements, audit opinions, or detailed financial performance data. It is not a full annual or interim report, nor is it a call transcript or management report. The document is relatively short (2354 characters) and serves as a regulatory disclosure about related-party transactions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-11 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.